[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610735":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":57,"collaborators":24,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":24,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":24,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":24,"overallStatus":42,"whyStopped":24,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1：Group A","EXPERIMENTAL","ZG006 Q3W",[13,14],"Drug: ZG006","Drug: Serplulimab",{"label":16,"type":10,"description":11,"interventionNames":17},"Part 1：Group B",[13,14],[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","ZG006","ZG006 will be administered as an IV infusion.",[9,16],null,{"type":20,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Serplulimab","Serplulimab will be administered as an IV infusion.",[9,16],[30],{"name":31,"affiliation":5,"role":32},"Jason Wu","STUDY_CHAIR",[34],{"name":35,"role":36,"phone":37,"phoneExt":24,"email":38},"Cong Zhang","CONTACT","17602176888","zhangc@zelgen.com",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Shanghai Chest Hospital","RECRUITING","Shanghai","Shanghai Municipality","200030","China","CN",{"type":49,"coordinates":50},"Point",[51,52],121.45806,31.22222,{"lat":52,"lon":51},[55],{"name":56,"role":36,"phone":24,"phoneExt":24,"email":24},"Shun Lu",{"type":58,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100610735","phase-1-study-of-zg006-in-combination-with-pd-1pd-l1-immune-checkpoint-inhibitors-as-first-line-standard-therapy-in-participants-with-extensive-stage-small-cell-lung-cancer-100610735",false,"NCT07231445","Study of ZG006 in Combination With PD-1\u002FPD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer","A Phase Ib Study Evaluating the Safety and Efficacy of ZG006 in Combination With PD-1\u002FPD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer","Inclusion Criteria:\n\n* Participants with histologically or cytologically confirmed ES-SCLC.\n* Fully understand the study and voluntarily sign the informed consent form;\n* Male or female 18\\~75 years of age;\n* Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;\n* Life expectancy ≥ 3 months;\n\nExclusion Criteria:\n\n* Participants were deemed unsuitable for participating in the study by the investigator for any reason.","ALL","18 Years","75 Years",{"count":70,"type":71},100,"ESTIMATED","INTERVENTIONAL",[74],"PHASE1","This is a randomized, multicenter, phase Ib study to evaluate the safety and efficacy of ZG006 combined with PD-1\u002FPD-L1 immune checkpoint inhibitors (±chemotherapy) as first-line therapy in Participants with extensive stage small cell lung cancer.",[77],"Small Cell Lung Cancer","2026-04-27",{"date":80,"type":81},"2026-04-28","ACTUAL",{"date":83,"type":81},"2026-04-21",{"date":85,"type":71},"2028-12",{"name":5,"class":6},1]